Heart Health
RNA-based drug shows promise for lowering blood pressure
Research we're watching
- Reviewed by Christopher P. Cannon, MD, Editor in Chief, Harvard Heart Letter; Editorial Advisory Board Member, Harvard Health Publishing
A single injection of a new RNA-based drug may lower blood pressure for up to six months, according to a small study published July 20, 2023, in The New England Journal of Medicine.
The drug, zilebesiran, is an example of a new class of drugs called small interfering RNA (siRNA) drugs. It works by interfering with the liver's production of angiotensinogen, a protein that plays a key role in high blood pressure.
Researchers tested seven different dosages of the drug in 107 people. Higher doses led to drops of at least 10 points in systolic blood pressure (the first number in a reading) and 5 points in diastolic blood pressure (the second number) after two months and the effects lasted for six months.
The changes stayed consistent throughout the day, and few side effects were reported. Two larger trials of the drug are currently under way.
Image: © Pua108/Getty Images
About the Author
Julie Corliss, Executive Editor, Harvard Heart Letter
About the Reviewer
Christopher P. Cannon, MD, Editor in Chief, Harvard Heart Letter; Editorial Advisory Board Member, Harvard Health Publishing
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
